Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Repros Therapeutics revenue
Repros Therapeutics's revenue is $2.3 billion.
What is Repros Therapeutics's revenue?
- Repros Therapeutics's revenue growth from 2019 to 2024 is 26.13%.
- Repros Therapeutics has 30 employees, and the revenue per employee ratio is $75,452,533.
- Repros Therapeutics's peak quarterly revenue was $684.0M in 2023(q1).
- Repros Therapeutics peak revenue was $2.4B in 2023.
- Repros Therapeutics annual revenue for 2023 was 2.4B, 5.24% growth from 2022.
- Repros Therapeutics annual revenue for 2024 was 2.3B, -3.86% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Repros Therapeutics historical revenue
Repros Therapeutics annual revenue
Repros Therapeutics annual revenue over time
| Fiscal year / year | Repros Therapeutics revenue |
|---|---|
| 2019 | $1.8B |
| 2020 | $2.1B |
| 2021 | $2.2B |
| 2022 | $2.2B |
| 2023 | $2.4B |
| 2024 | $2.3B |
How accurately did Repros Therapeutics' revenue projections match actual performance?
Repros Therapeutics annual growth
Repros Therapeutics annual growth rate over time
| Year | Repros Therapeutics growth |
|---|---|
| 2020 | 17%↑ |
| 2021 | 6%↑ |
| 2022 | 0%↑ |
| 2023 | 5%↑ |
| 2024 | -4%↓ |
Repros Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Repros Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2022 | $545.1M | $517.9M | $552.8M | $564.4M |
| 2023 | $684.0M | $538.2M | $536.3M | $596.1M |
| 2024 | $568.0M | $537.3M | $564.7M | $593.6M |
Repros Therapeutics jobs nearby
Do you work at Repros Therapeutics?
Is Repros Therapeutics transparent about its revenue structure?
Repros Therapeutics financing
Repros Therapeutics received early financing of $5.9M on 2009-11-12.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $5.9M | 11/2009 |
| Post Ipo Equity | $23.6M | 09/2012 |
Repros Therapeutics competitors
Repros Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
Repros Therapeutics's smallest competitor is ArTara Therapeutics with revenue of $284.9K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | $85,008 | $2.0B | 900 | - |
| Exelixis | $108,978 | $2.2B | 484 | 113 |
| Sarepta Therapeutics | $94,985 | $1.9B | 840 | 27 |
| Acadia Pharmaceuticals | $90,533 | $957.8M | 570 | 54 |
| Merck | $90,328 | $64.2B | 74,000 | 1,464 |
| Medivation | $94,135 | $1.0B | 628 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 600 |
| ArTara Therapeutics | $49,216 | $284.9K | 5 | - |
| NeoGenomics Laboratories | $62,740 | $660.6M | 1,500 | 60 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Repros Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Repros Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Repros Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Repros Therapeutics. The data presented on this page does not represent the view of Repros Therapeutics and its employees or that of Zippia.
Repros Therapeutics may also be known as or be related to REPROS THERAPEUTICS INC., Repros Therapeutics, Repros Therapeutics Inc and Repros Therapeutics Inc.